Reviewing Mangoceuticals (MGRX) and Its Rivals

Insider & Institutional Ownership

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 39.3% of Mangoceuticals shares are owned by company insiders. Comparatively, 28.0% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Mangoceuticals has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Mangoceuticals’ competitors have a beta of 3.73, meaning that their average share price is 273% more volatile than the S&P 500.

Valuation & Earnings

This table compares Mangoceuticals and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mangoceuticals	$866,792.00	-$9.21 million	-0.37
Mangoceuticals Competitors	$2.48 billion	$61.83 million	11.09

Mangoceuticals’ competitors have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Mangoceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-1,053.93%	-243.34%	-200.73%
Mangoceuticals Competitors	-742.83%	-44.77%	-34.17%

Summary

Mangoceuticals competitors beat Mangoceuticals on 8 of the 9 factors compared.

Mangoceuticals Company Profile

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.